Status:
UNKNOWN
MRD Application in Colorectal Cancer Patients
Lead Sponsor:
Shandong First Medical University
Collaborating Sponsors:
Jinan Central Hospital
Conditions:
Colorectal Cancer
Surgery
Eligibility:
All Genders
30-80 years
Brief Summary
We first collect tumor tissue and adjacent tissue to peform the WES sequencing, then collect blood after postoperative surgery 1, 3. 6, 9, 12, 18, 24 month to detect ctDNA.
Detailed Description
ctDNA is obtained from plasma rather than serum, as the latter contains more DNA released from immune cells during clotting. Blood should be drawn into a K2EDTA or cell stabilization tube (e.g., Strec...
Eligibility Criteria
Inclusion
- (1) Patients with colorectal tumors, whose clinical symptoms meet the diagnostic criteria of colon cancer in my country, and pathologically diagnosed as colorectal cancer after surgery; (2) patients with stage II-III colorectal cancer; (3) aged 30-80 years; (4) All underwent conventional radiotherapy and chemotherapy after operation; (5) Complete clinical data and follow-up records were available.
Exclusion
- (1) Other serious diseases (cardiovascular and cerebrovascular diseases, kidney diseases, etc.) before operation; (2) Combined with multiple primary colorectal cancers; (3) Patients with other malignant tumors within the past 5 years; (4) Combined with digestive tract Obstruction, perforation, bleeding and other indications for emergency surgery.
Key Trial Info
Start Date :
January 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06028516
Start Date
January 6 2021
End Date
December 31 2024
Last Update
April 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinan central hospital affiliated to Shandong First Medical University
Jinan, Shandong, China, 250017